Samsung Biologics

Samsung Biologics's reported carbon emissions

Samsung Biologics, a Pharmaceutical Preparation Manufacturing company headquartered in South Korea (KR), has reported its carbon emissions for several years. For the year 2024, the company's total reported emissions were approximately 636,209,000 kg CO2e. This total comprises Scope 1 emissions of about 71,971,718 kg CO2e, Scope 2 emissions (market-based) of approximately 115,827,854 kg CO2e, and Scope 3 emissions totalling around 448,410,157 kg CO2e. In 2023, Samsung Biologics's total emissions were approximately 696,378,000 kg CO2e. This included Scope 1 at roughly 69,262,496 kg CO2e, Scope 2 (market-based) at about 113,313,391 kg CO2e, and Scope 3 at approximately 513,803,084 kg CO2e. The company's total emissions for 2022 were approximately 946,205,000 kg CO2e, with Scope 1 at around 54,575,447 kg CO2e, Scope 2 (market-based) at approximately 99,917,630 kg CO2e, and Scope 3 at roughly 791,712,059 kg CO2e. Samsung Biologics has established significant climate commitments. The company aims for net zero by 2050 or earlier. To achieve this, they have set interim milestones, including a target to reduce direct (Scope 1) emissions by 32% by 2030 and by 62% by 2040, using 2022 as the baseline year. Furthermore, they aim to reduce their suppliers' emissions by 36% by 2030 and by 73% by 2040, also based on the 2022 baseline. These targets are classified as net zero and cover all scopes.